176 related articles for article (PubMed ID: 37594848)
1. Real-world primary nonadherence to antiobesity medications.
Kan H; Bae JP; Dunn JP; Buysman EK; Gronroos NN; Swindle JP; Bengtson LGS; Ahmad N
J Manag Care Spec Pharm; 2023 Oct; 29(10):1099-1108. PubMed ID: 37594848
[No Abstract] [Full Text] [Related]
2. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study.
Watkins S; Toliver JC; Kim N; Whitmire S; Garvey WT
J Manag Care Spec Pharm; 2022 Oct; 28(10):1066-1079. PubMed ID: 35856489
[No Abstract] [Full Text] [Related]
3. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.
Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B
Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358
[No Abstract] [Full Text] [Related]
4. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
Song JE; Ko HJ; Kim AS
Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
[TBL] [Abstract][Full Text] [Related]
5. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
[TBL] [Abstract][Full Text] [Related]
6. Persistence of newer anti-obesity medications in a real-world setting.
Ganguly R; Tian Y; Kong SX; Hersloev M; Hobbs T; Smolarz BG; Ramasamy A; Haase CL; Weng W
Diabetes Res Clin Pract; 2018 Sep; 143():348-356. PubMed ID: 30009937
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
Kim N; Wang J; Burudpakdee C; Song Y; Ramasamy A; Xie Y; Sun R; Kumar N; Wu EQ; Sullivan SD
J Manag Care Spec Pharm; 2022 Jul; 28(7):740-752. PubMed ID: 35737858
[No Abstract] [Full Text] [Related]
8. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.
Pantalone KM; Smolarz BG; Ramasamy A; Baz Hecht M; Harty BJ; Rogen B; Griebeler ML; Borukh E; Young JB; Burguera B
JAMA Netw Open; 2021 Jul; 4(7):e2116595. PubMed ID: 34255049
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
Czepiel KS; Perez NP; Campoverde Reyes KJ; Sabharwal S; Stanford FC
Front Endocrinol (Lausanne); 2020; 11():290. PubMed ID: 32477270
[TBL] [Abstract][Full Text] [Related]
10. Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.
Gasoyan H; Pfoh ER; Schulte R; Sullivan E; Le P; Rothberg MB
Diabetes Obes Metab; 2024 May; 26(5):1687-1696. PubMed ID: 38287140
[TBL] [Abstract][Full Text] [Related]
11. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
Levin A; Kaur N; Mainoo NK; Perez A
Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
[TBL] [Abstract][Full Text] [Related]
13. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims.
Schrader R; Posner N; Dorling P; Senerchia C; Chen Y; Beaverson K; Seare J; Garnier N; Walker V; Alvir J; Mahn M; Merla V; Zhang Y; Landis C; Buikema AR
J Manag Care Spec Pharm; 2023 Sep; 29(9):1033-1044. PubMed ID: 37610111
[No Abstract] [Full Text] [Related]
14. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.
Calderon G; Gonzalez-Izundegui D; Shan KL; Garcia-Valencia OA; Cifuentes L; Campos A; Collazo-Clavell ML; Shah M; Hurley DL; Abu Lebdeh HS; Sharma M; Schmitz K; Clark MM; Grothe K; Mundi MS; Camilleri M; Abu Dayyeh BK; Hurtado Andrade MD; Mokadem MA; Acosta A
Int J Obes (Lond); 2022 Mar; 46(3):555-563. PubMed ID: 34811486
[TBL] [Abstract][Full Text] [Related]
15. Antiobesity Medication Use Among Overweight and Obese Adults in the United States: 2015-2018.
MacEwan J; Kan H; Chiu K; Poon JL; Shinde S; Ahmad NN
Endocr Pract; 2021 Nov; 27(11):1139-1148. PubMed ID: 34265455
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a drug adherence index for COPD.
Bengtson LGS; Bancroft T; Schilling C; Buikema AR; Stanford RH
J Manag Care Spec Pharm; 2021 Feb; 27(2):198-209. PubMed ID: 33506734
[No Abstract] [Full Text] [Related]
19. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
